Vertex Pharmaceuticals VRTX stock has formed a Bullish FlagThe bullish flag breakout pattern is a popular chart pattern in technical analysis that signals the continuation of an uptrend. It typically forms after a strong price surge, where... breakout on pattern on June 12, 2023. The stock is in a technical strong uptrend.
Vertex Pharmaceuticals is a biotechnology company that develops and manufactures drugs for the treatment of serious and life-threatening diseases such as cystic fibrosis, Huntington’s disease, and sickle cell disease. The company focuses on developing small molecule drugs that target specific genetic mutations, aiming to address the underlying cause of a disease rather than just treating its symptoms. Vertex’s most successful drug to date is a treatment for cystic fibrosis called Kalydeco, which has dramatically improved the lives of patients with certain genetic mutations.
Vertex Pharmaceuticals presents data on CFTR modulators at ECFS Conference
On June 9, 2023, Vertex Pharmaceuticals announced that 12 scientific abstracts on the company’s portfolio of cystic fibrosis medicines were presented at this year’s European Cystic Fibrosis Society’s 46th European Cystic Fibrosis Conference held June 7-10, 2023, in Vienna, Austria. Together, the data presented show the long-term benefits of treatment with CFTR modulators as well as the importance of treating the underlying cause of CF as early in life as possible.
Vertex presented an interim analysis of a registry-based study of real-world data collected from people with CF and treated with TRIKAFTA, also known in the European Union and in the U.K. as KAFTRIO in combination with ivacaftor, including over 16,000 people with CF from the Cystic Fibrosis Foundation Patient Registry and nearly 3,000 from the German CF Registry. This ongoing five-year post-authorization study is the largest real-world study of people with CF treated with TRIKAFTA to date.
The IA showed clinically significant disease-modifying benefits for TRIKAFTA, including improved lung function and a 79% reduction of pulmonary exacerbations in the U.S. and 83% in Germany overall compared to pre-TRIKAFTA baseline. The rate of death was 72% lower in the U.S. and 82% lower in Germany, the rate of lung transplant was 85% lower in the U.S. and 100% lower in Germany, compared to 2019 U.S. CFFPR and German CF Registry populations. No new safety concerns were identified.
Vertex also presented final results of the nearly four-year TRIKAFTA open-label follow-up study of the Phase 3 pivotal trials in people with CF ages 12 years and older with at least one F508del mutation in the CFTR gene. The results of this study are unprecedented, showing for the first time that treatment with TRIKAFTA resulted in no decline in lung function over a four-year period.
